Literature DB >> 2069847

Monitoring therapeutic response to tamoxifen in NMU-induced rat mammary tumours by 31P MRS.

S Baluch1, C J Midwood, J R Griffiths, M Stubbs, R C Coombes.   

Abstract

Tamoxifen injections were given once a week for 4 weeks to 19 rats bearing N-methyl-N-nitrosourea (NMU)-induced mammary carcinomas. NMR spectra were collected on days 2, 7, 14, 21 and 28. Only 42% of the tumours responded to the tamoxifen in that they regressed significantly; another 21% did not change in size and 37% grew significantly. In the ones that did subsequently regress there were significant changes in the NTP/Pi ratio as early as 2 days after treatment, before any detectable change in volume was recorded, and continuing up to 21 days. The significance of these findings and the possible mechanisms underlying the changes are discussed.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 2069847      PMCID: PMC1972538          DOI: 10.1038/bjc.1991.198

Source DB:  PubMed          Journal:  Br J Cancer        ISSN: 0007-0920            Impact factor:   7.640


  12 in total

1.  In-vivo 31P magnetic resonance spectroscopy for monitoring treatment response in breast cancer.

Authors:  J Glaholm; M O Leach; D J Collins; J Mansi; J C Sharp; A Madden; I E Smith; V R McCready
Journal:  Lancet       Date:  1989-06-10       Impact factor: 79.321

2.  Phosphorus-31 magnetic resonance spectroscopy and blood perfusion of the RIF-1 tumor following X-irradiation.

Authors:  G M Tozer; Z M Bhujwalla; J R Griffiths; R J Maxwell
Journal:  Int J Radiat Oncol Biol Phys       Date:  1989-01       Impact factor: 7.038

3.  In vivo 31P nuclear magnetic resonance spectroscopy of subcutaneous 9L gliosarcoma: effects of tumor growth and treatment with 1,3-bis(2-chloroethyl)-1-nitrosourea on tumor bioenergetics and histology.

Authors:  R G Steen; R J Tamargo; K A McGovern; S S Rajan; H Brem; J P Wehrle; J D Glickson
Journal:  Cancer Res       Date:  1988-02-01       Impact factor: 12.701

4.  31P-nuclear magnetic resonance spectroscopy studies of the response of rat mammary tumors to endocrine therapy.

Authors:  L M Rodrigues; C J Midwood; R C Coombes; A N Stevens; M Stubbs; J R Griffiths
Journal:  Cancer Res       Date:  1988-01-01       Impact factor: 12.701

5.  In vivo 31P NMR study of the metabolism of murine mammary 16/C adenocarcinoma and its response to chemotherapy, x-radiation, and hyperthermia.

Authors:  W T Evanochko; T C Ng; M B Lilly; A J Lawson; T H Corbett; J R Durant; J D Glickson
Journal:  Proc Natl Acad Sci U S A       Date:  1983-01       Impact factor: 11.205

Review 6.  Response of solid tumors to chemotherapy monitored by in vivo 31P nuclear magnetic resonance spectroscopy: a review.

Authors:  R G Steen
Journal:  Cancer Res       Date:  1989-08-01       Impact factor: 12.701

7.  31P nuclear magnetic resonance spectroscopy studies of tumor energy metabolism and its relationship to intracapillary oxyhemoglobin saturation status and tumor hypoxia.

Authors:  E K Rofstad; P DeMuth; B M Fenton; R M Sutherland
Journal:  Cancer Res       Date:  1988-10-01       Impact factor: 12.701

8.  Blood flow, oxygen consumption, and tissue oxygenation of human breast cancer xenografts in nude rats.

Authors:  P Vaupel; H P Fortmeyer; S Runkel; F Kallinowski
Journal:  Cancer Res       Date:  1987-07-01       Impact factor: 12.701

Review 9.  Application of in vivo NMR spectroscopy to cancer.

Authors:  W T Evanochko; T C Ng; J D Glickson
Journal:  Magn Reson Med       Date:  1984-12       Impact factor: 4.668

10.  31P-NMR spectroscopy and histological studies of the response of rat mammary tumours to endocrine therapy.

Authors:  M Stubbs; R C Coombes; J R Griffiths; R J Maxwell; L M Rodrigues; B A Gusterson
Journal:  Br J Cancer       Date:  1990-02       Impact factor: 7.640

View more
  1 in total

1.  Cancer stem cell theory and the warburg effect, two sides of the same coin?

Authors:  Nicola Pacini; Fabio Borziani
Journal:  Int J Mol Sci       Date:  2014-05-19       Impact factor: 5.923

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.